Summary of the Conference Call for Smoore International Company Overview - Smoore International is transitioning from an electronic vapor company to a platform company focused on heated not-burn (HNB) technology, collaborating with firms like British American Tobacco to advance new tobacco products in response to the declining traditional cigarette market [2][5]. Industry Trends - The global traditional cigarette market is experiencing a continuous decline, with a significant drop in per capita smoking rates in the U.S. by 30% to 40% since 1970. The smoking population and consumption have decreased by approximately 1% annually over the past 20 years [7]. - New tobacco products, including HNB and oral products, are seen as key to overcoming the challenges faced by traditional tobacco companies. HNB and oral products are more suitable for large traditional tobacco firms, while the vapor electronic cigarette market is dominated by Chinese manufacturers [10]. Key Points on Smoore's Business - Smoore's HNB products are gaining market share in Japan, Italy, and Poland, indicating strong market performance and growth potential. For instance, Japan saw a 1.4% increase in market share within three months [11]. - The market valuation of Smoore is considered conservative, with future growth expected primarily from HNB business expansion. Achieving sales of over 10 billion units by 2026 could lead to a significant leap in performance [13]. - Smoore's U.S. subsidiary is focused on the medical vaporization sector and has applied for FDA certification, investing approximately 400 million yuan annually in R&D. This segment is expected to become a new growth point within three years [19]. Financial Projections and Market Expectations - Smoore has set ambitious market capitalization targets of 300 billion, 400 billion, and 500 billion yuan by 2025, despite its current valuation being in the hundreds of billions [4]. - The traditional electronic vapor market is stabilizing, with an expected annual growth rate of over 10% [3][18]. - The company anticipates that its HNB business could contribute significantly to its valuation, with estimates suggesting a sales share of 10-15% from HNB products, potentially leading to substantial profit elasticity [16][17]. Future Outlook - The domestic new tobacco market in China is expected to grow significantly, with Smoore positioned to benefit from this shift. The potential transition towards new tobacco products in China could create vast market opportunities [14]. - The medical vaporization segment is seen as a third growth curve for Smoore, with expectations for commercialization and revenue generation within three years [19][20]. Conclusion - Smoore International is strategically positioned to capitalize on the evolving tobacco landscape, with a focus on HNB technology and medical applications. The company's growth potential is supported by its innovative R&D efforts and collaborations with major tobacco firms, setting the stage for a promising future in the new tobacco market.

Summary of Smoore International's Conference Call Company Overview - **Company**: Smoore International - **Industry**: Electronic smoking devices and related products Key Points and Arguments Financial Performance - **Q3 Revenue Growth**: Smoore International reported a 27.5% increase in revenue for Q3 2025, exceeding market expectations, with adjusted profit rising by 4.8% quarter-over-quarter [2][3] - **HNB Product Sales**: The strong performance was driven by robust sales of Heat-Not-Burn (HNB) products, with expectations of at least 1.2 billion RMB in annual revenue from HNB [3][4] - **Traditional Vaping Products**: The traditional vaping segment also saw significant growth, particularly in Europe, due to the introduction of new products following a ban on disposable e-cigarettes [2][3] Market Dynamics - **European Market**: The European market outperformed overall company growth, driven by regulatory changes and the introduction of new products [2][5] - **U.S. Market Recovery**: The U.S. market is recovering more slowly, but stricter regulations on compliant products are creating opportunities for Smoore's partners, such as British American Tobacco's VUSE brand [5] Strategic Initiatives - **Expansion of HNB Markets**: Smoore is entering more core markets for HNB products, including Poland and Italy, aiming to transition from the initial development phase to a more expansive growth phase [7] - **Collaboration with British American Tobacco**: The partnership with British American Tobacco is seen as a significant growth opportunity, enhancing Smoore's product offerings and market reach [4][10] Product Development - **Medical Nebulization**: Smoore is investing heavily in the medical nebulization sector, with expectations to generate revenue starting in 2026. The company has submitted multiple products for FDA approval [4][11] - **Free Brand WAPER**: The company is increasing market share for its free brand WAPER through enhanced channel coverage and localized operations, despite limited elasticity in this segment [6] Future Outlook - **Profitability Expectations**: While current profits are not exceptionally high, Smoore anticipates improved profitability from 2026 onwards, driven by regulatory changes and market share expansion [9] - **Valuation and Market Potential**: Following recent stock price adjustments, Smoore's valuation is seen as attractive, with a static P/E ratio of 58x for 2025, expected to drop to 39x in 2026 and 29x in 2027, indicating significant future earnings potential [12] Long-term Growth Areas - **Beauty Nebulization**: The beauty nebulization segment is part of Smoore's long-term strategy, expected to follow the medical nebulization developments, with promising growth potential [13] New Business Contributions - **Initial Profit Contributions**: New business segments are expected to have limited profit contributions initially, which is typical for early-stage promotions. The focus is on market share, with profitability expected to improve as sales volumes increase in subsequent years [14] Additional Important Insights - **Production Capacity**: Smoore has automated production capabilities for 2 million devices and plans to increase this to over 5 million, with monthly production of 2 million cartridges [10] - **Market Positioning**: Smoore positions itself as a technology platform, providing differentiated solutions to various tobacco companies, not just British American Tobacco [7][8]

Group 1: Company Developments - Transpire Bio, a wholly-owned subsidiary of Smoore International, has submitted an Abbreviated New Drug Application (ANDA) for Breo® Ellipta® and received acceptance from the FDA on September 23 [1][1] - If approved, Transpire Bio will have a 180-day exclusivity period in the U.S. market for Breo® Ellipta®, which is used for the maintenance treatment of asthma and COPD, with projected sales of $2.02 billion in 2024 [1][1] - This breakthrough highlights Transpire Bio's strategic positioning in the complex generic drug sector and strengthens Smoore International's innovative advantage in the global inhalation drug market [1][1] Group 2: Industry Trends - The FDA has launched a pilot program to enhance the efficiency of pre-market tobacco product applications (PMTAs) for nicotine pouch products, aiming for more frequent feedback and shorter review times [2][2] - The pilot program reflects the FDA's commitment to improving regulatory efficiency while maintaining scientific standards for tobacco product reviews [2][2] - As of now, the FDA has authorized 20 nicotine pouch products, with potential for more varieties in the future [2][2] Group 3: Export Data - In the first eight months of 2025, the export value of e-cigarettes and similar personal vaporizing devices reached $2.116 billion, a year-on-year increase of 14.55%, while other non-combustible nicotine products saw a decrease of 18.31% [3][3] - In August 2025, the export value of e-cigarettes was $301 million, up 34.01% year-on-year, while other nicotine products reached $635 million, down 5.68% year-on-year [3][3] - The average export price for e-cigarettes was $4.46 per unit, with an overall export price of $45.07 per kilogram in August [3][3] Group 4: Regional Insights - The top five export destinations (U.S., U.K., Germany, South Korea, UAE) accounted for 62.32% of total exports in the first eight months of 2025, a slight decrease of 0.56 percentage points year-on-year [4][4] - The U.S. remains the largest market with an export value of $2.199 billion, down 8.67% year-on-year, representing 33.56% of total exports [4][4] - Notable growth was observed in exports to the UAE and Indonesia, with increases of 60.57% and 67.25% respectively, while South Korea, Russia, and the Netherlands experienced significant declines [4][4]